Pfizer Inc (NYSE: PFE). is a worldwide pharmaceutical and biotechnology company with its main office in Manhattan, New York City, on 42nd Street. The business was founded in 1849. Pfizer is well recognized as an industry leader in biopharmaceutical research for developing the COVID-19 vaccine.
Moderna, Inc. (NASDAQ: MRNA) is a Cambridge, Massachusetts-based pharmaceutical and biotechnology business specializing in mRNA vaccines and other RNA treatments. The Moderna COVID-19 vaccine, sometimes known as Spikevax, is the only commercially available item for the company.
Pfizer and Moderna are the two largest pharmaceutical corporations in the United States. If you want to add one to your portfolio, this article will study and compare the two to make your decision easier.
Pfizer VS Moderna Third Quarter Earnings And Revenue
MODERNA: Specifically, because of a reduction in sales of the Company's COVID-19 vaccines, total revenue for the third quarter of 2022 was $3.4 billion as opposed to $5.0 billion at the same time in 2021. Compared to the same period in 2021, product sales for the third quarter of 2022 were $3.1 billion, a 35% decrease. This decline was primarily attributable to lower sales volume brought on by the timing of market authorizations for our COVID-19 bivalent boosters and the ensuing manufacturing ramp-up.
The business reported $1.04 billion in net profits for the quarter, a 68% decrease from the prior year. The Covid vaccination is expected to generate between $18 billion and $19 billion in revenue for Moderna this year. This is attributed to supply chain issues that delayed the delivery of several vaccines until 2023.
PFIZER: Due to waning demand for its Covid vaccines abroad, Pfizer saw a 6% decline in third-quarter global revenue to $22.6 billion from the same period in 2017. In the third quarter, the company sold its vaccine for $4.4 billion globally, a 66% decrease from the same period in 2021. It anticipates earnings per share of $6.40 to $6.50 for the year, up from its previous forecast of $6.30 to $6.45. Pfizer's net income for the third quarter was $8.6 billion, up 6% over the same period last year.
Pfizer VS Moderna P/E Ratio
From a value standpoint, the P/E ratio can assist us in evaluating which of the two is less expensive. Pfizer Inc. (NYSE: PFE) has a trailing 12-month P/E of 7.71X, while the Large Cap Pharmaceuticals industry has a P/E of 14.37X.
Moderna, Inc. (NASDAQ: MRNA) has a trailing-12-month P/E of 6.48X, while the Medical - Biomedical and Genetics industry has a P/E of 18.99X.
According to our research, Moderna stocks are significantly less expensive than Pfizer because they have a lower P/E ratio. A high price-to-earnings ratio indicates that the company is overvalued.
Pfizer Vs Moderna In Dividends
Pfizer's(NYSE: PFE) Trailing twelve months (TTM) dividend payout is $1.60 as of December 08, 2022. Pfizer's current dividend yield is 3.22% as of December 8, 2022.
Pfizer pays dividends and currently has a higher dividend yield of 3.22% over the sector average of 1.57%. As a result, PFE stock can provide you with income while expanding your investment.
Moderna(NASDAQ: MRNA) pays no dividends.
Pfizer Vs Moderna In Developing Future Projects
Pfizer (NYSE: PFE) has a more diverse business. Pfizer plans to launch five "new vaccines" and two oncology and immuno-inflammation medicines next year.
Moderna (NASDAQ: MRNA) has not made any public statement about future projects. Moderna's revenues are currently primarily tied to its COVID-19 products.
Based on the above analysis, Pfizer (PFE) appears to be a more profitable stock to add to your portfolio. Pfizer stock will be profitable in the long run, from third-quarter earnings and revenues to creating future ventures. Pfizer is our experts' choice here over Moderna.
Rate this article